Acceleron Pharma Competitors and Similar CompaniesClear all
Acceleron Pharma's competitors and similar companies include Portola Pharmaceuticals, GBT (Global Blood Therapeutics), Theravance Biopharma and Supernus Pharmaceuticals.
 GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. |  Theravance Biopharma Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. |  Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. | |||
Founding Date | Founding Date 2003 | Founding Date 2003 | Founding Date 2012 | Founding Date 1996 | Founding Date 2005 |
Type | Type Subsidiary | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ Zug, CH | Locations South San Francisco, US HQ Planegg, DE Amsterdam, NL | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB | Locations Dublin, IE HQ San Francisco, US | Locations Rockville, US HQ |
Employees | Employees 636% decrease | Employees 55 | Employees 352106% increase | Employees 97 | Employees 6527% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 4.4 b | Valuation ($) 429 m | Valuation ($) 1.9 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $92.5m (FY, 2020) | Revenue (est.) $116.6m (FY, 2019) | Revenue (est.) $194.7m (FY, 2021) | Revenue (est.) $107.5m (FY, 2025) | Revenue (est.) $719m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $44.4m (FY, 2019) | Cost of goods $3.3m (FY, 2021) | Cost of goods N/A | Cost of goods $74.6m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $72.3m (FY, 2019) | Gross profit N/A | Gross profit $107.5m (FY, 2025) | Gross profit $644.4m (FY, 2025) |
Net income | Net income ($166m) (FY, 2020) | Net income ($290.7m) (FY, 2019) | Net income ($303.1m) (FY, 2021) | Net income $105.9m (FY, 2025) | Net income ($38.6m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 141.8m | Total funding raised $ 295.1m | Total funding raised $ 88.7m | Total funding raised $ 55m | Total funding raised $ 69.5m |
For sources of this data, please see the company profile
View Company Profiles
Portola Pharmaceuticals
HQ
South San Francisco, US
Portola Pharmaceuticals is a biopharmaceutical company.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View companyTheravance Biopharma
HQ
Dublin, IE
Employees
97
Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses.
View companySupernus Pharmaceuticals
HQ
Rockville, US
Employees
652↑ 7% increase
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders.
View company